CONTRAST SENSITIVITY NEWS ARTICLES

News About Contrast Sensitivity Testing with the CSV-1000

CSV-1000 Excellent for Detecting Subclinical Visual Involvement in Multiple Sclerosis
A recent study published from the University of Bari, Bari, Italy showed that contrast sensitivity, as measured with the CSV-1000, was the most sensitive tool for detecting early visual involvement in multiple sclerosis. Data showed that the CSV-1000 detected abnormal results in 77% of the eyes, while VEP, Frequency Doubling Perimetry, SAP, and MRI detected 54.4%, 50%, 63.6% and 72.7% abnormal results, respectively. Click Here for Article

CSV-1000 Contrast Sensitivity Demonstrates Improvement After Surgical Reduction of Intraocular Pressure in Unilateral Glaucoma
Prof Stephano Gandolfi, a well known glaucoma specialist from Parma Italy, recently published the results of a 3 year study evaluating unilateral glaucoma patients who underwent surgery to reduce IOP. These patients had early cupping, but no field loss. Patients showed dramatic improvement in contrast sensitivity, with no changes in other measures (other than the reduction of IOP following surgery). The authors suggest that improvement in central visual function, as measured by contrast sensitivity, should be used as a metric to assess the efficacy of glaucoma treatment. Click Here for Article

Verisyse Lens Provides Better Contrast Sensitivity
The Verisyse lens is a new Intraocular lens introduced as a promising treatment for the correction of nearsightedness and astigmatism. Prof Burkhardt Dick from Mainz Germany demonstrated in his research that patients had significantly improved contrast sensitivity, as measured with the CSV-1000, after the implantation of the Verisyse lens. Click Here for Article

Use of Contrast Sensitivity to Monitor Drug Therapy
Below is a recently published article in Ophthalmology Management describing the use of contrast sensitivity for evaluating and tracking drug treatment. The CSV-1000 is shown to be very useful for determining response to medications in glaucoma patients and for evaluating treatment in patients with Age Related Macular Degeneration (ARMD). *This article is no longer available on-line, please contact the VectorVision offices for the full text version of the article.

Evaluation of Potential Neuroprotective Effects with CSV-1000
This study, published in British Journal of Ophthalmology, shows that newly diagnosed and previously untreated patients who had an initial treatment with Betagan show a significant improvement in contrast sensitivity, as measured with the VectorVision CSV-1000. A similar group of patients showed no improvement in contrast sensitivity when treated with TimopticXE, even though both groups had similar reductions in IOP. The study concludes that the improvement in vision may be related to some IOP independent factor, potentially neuroprotection. Click Here for Article

Evaluation of Epilepsy Patients with CSV-1000
The study below describes how contrast sensitivity testing, with the CSV-1000, can be used to assess central vision deficits in epilepsy patients treated with vigabatrin. Eight of 15 patients demonstrate abnormal contrast sensitivity results. Click Here for Article

Traumatic Brain InjuryTBI Legal Issues Primary Pulmonary Hypertension, Mesothelioma, Other Resource